From signal to alert: A cluster of exposures to counterfeit alprazolam tablets containing five novel benzodiazepines
Rebekka Syrjanen, Jennifer Schumann, Sarah E. Hodgson, Rachelle Abouchedid, Joe‐Anthony Rotella, Andis Graudins, Shaun L. Greene
Abstract
OBJECTIVE: To illustrate the toxicosurveillance role of the Emerging Drugs Network of Australia - Victoria (EDNAV) project in informing timely harm minimisation interventions. METHODS: Utilisation of an ethics approved clinical registry storing de-identified clinical and analytical data on Victorian ED illicit drug-related presentations. RESULTS: In April 2022, six adults presented to hospital with varying levels of sedation, following the use of counterfeit benzodiazepines. Comprehensive toxicological analysis identified five separate novel benzodiazepines within blood samples from each patient. A public 'Drug Alert' was subsequently issued, and local emergency physicians were notified. CONCLUSION: Toxicosurveillance projects, such as EDNAV, are critical to the continued monitoring and reporting of illicit substance use in the community.